Raphaël Poyet

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Point-of-Care Testing

Impact of Obesity and the Metabolic Syndrome on Response to Clopidogrel or Prasugrel and Bleeding Risk in Patients Treated After Coronary Stenting

Assays of different aspects of haemostasis – what do they measure?

Clopidogrel with or without Omeprazole in Coronary Artery Disease

High Residual Platelet Reactivity After Clopidogrel Loading and Long-term Cardiovascular Events Among Patients With Acute Coronary Syndromes Undergoing PCI

High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study

Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome

Omeprazole and clopidogrel: Should clinicians be worried?

The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary

Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients

CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome

Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration

Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite

Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis

The Year in Non–ST-Segment Elevation Acute Coronary Syndrome

Pharmacokinetic interactions of curcuminoids with conventional drugs: A review

Clopidogrel–Drug Interactions

Impact of Genetic Polymorphisms and Drug – Drug Interactions on Clopidogrel and Prasugrel Response Variability

Management of Patients With Ulcer Bleeding

Aspirin and Antiplatelet Agent Resistance

Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications

Update on Myocarditis

Clopidogrel and proton pump inhibitors - where do we stand in 2012?

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Platelet function testing and risk of bleeding complications

Triple Therapy With Aspirin, Prasugrel, and Vitamin K Antagonists in Patients With Drug-Eluting Stent Implantation and an Indication for Oral Anticoagulation

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease

Platelet Function Tests in Clinical Cardiology

Platelet Function Testing in Contemporary Clinical and Interventional Practice

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

The ethics of algorithms: Mapping the debate

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons

Governing artificial intelligence: ethical, legal and technical opportunities and challenges

The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects

Aspirin and Antiplatelet Agent Resistance

Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Cardiac Involvement with Parasitic Infections

Moral Crumple Zones: Cautionary Tales in Human-Robot Interaction (WeRobot 2016)

Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention

2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome.

Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome.

Accident coronarien aigu révélé par un œdème pulmonaire survenu en plongée sous-marine

Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting

Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting

Myocardite àTrichinella spiralis : à propos d’un cas

Predictive Values of Post-Treatment Adenosine Diphosphate–Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients

Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose